Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: An investigator-initiated trial and in vivo study

Stem Cells

Volumn 32, Issue 10, 2014, Pages 2724-2731

  Kim, Hyun Young ^a   Kim, Heejaung ^b   Oh, Ki Wook ^a   Oh, Seong Il ^a   Koh, Seong Ho ^a   Baik, Wonki ^a   Noh, Min Young ^a   Kim, Kyung Suk ^c   Kim, Seung Hyun ^a  

^a Hanyang University   (South Korea)

^b Daegu Gyeongbuk Medical Innovation Foundation   (South Korea)

^c Division of Dg and Ai Business   (South Korea)

Author keywords

Amyotrophic lateral sclerosis; Biological marker; In vivo study; Investigator initiated trial; Mesenchymal stromal cell

Indexed keywords

ANGIOGENIN; BETA FIBROBLAST GROWTH FACTOR 2; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 10; INTERLEUKIN 4; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL COUNT; CELL CULTURE; CELL ISOLATION; CELL LEVEL; CELL MIGRATION; CELL SURVIVAL; CISTERNA MAGNA; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HUMAN CELL; IN VIVO STUDY; LIFESPAN; MALE; MESENCHYMAL STROMA CELL; MOTONEURON; MOUSE; NONHUMAN; OPEN STUDY; PREDICTIVE VALUE; PREDICTOR VARIABLE; RATING SCALE; TREATMENT RESPONSE; ANIMAL; AUTOTRANSPLANTATION; CLINICAL TRIAL; CYTOLOGY; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOLOGICAL MARKERS; CELL COUNT; FEMALE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MIDDLE AGED; MOTOR NEURONS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84908099375     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1770     Document Type: Article

References (42)

1. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2:806-819.
2. de Carvalho M, Costa J, Swash M. Clinical trials in ALS: A review of the role of clinical and neurophysiological measurements. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:202-212.
3. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591.
4. Miller RG, Mitchell JD, Lyon M et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:191-206.
5. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 2007;213:341-347.
6. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284: 143-147.
7. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98:1076-1084.
8. Zhang M, Mal N, Kiedrowski M et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 2007;21: 3197-3207.
9. Koh SH, Baik W, Noh MY et al. The functional deficiency of bone marrow mesenchymal stromal cells in ALS patients is proportional to disease progression rate. Exp Neurol 2012;233:472-480.
10. Sadan O, Melamed E, Offen D. Bonemarrow- derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther 2009;9:1487-1497.
11. Joyce N, Annett G, Wirthlin L et al. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med 2010; 5:933-946.
12. Boucherie C, Caumont AS, Maloteaux JM et al. In vitro evidence for impaired neuroprotective capacities of adult mesenchymal stem cells derived from a rat model of familial amyotrophic lateral sclerosis (hSOD1(G93A)). Exp Neurol 2008;212:557-561.
13. Ohnishi S, Ito H, Suzuki Y et al. Intrabone marrow-bone marrow transplantation slows disease progression and prolongs survival in G93A mutant SOD1 transgenic mice, an animal model mouse for amyotrophic lateral sclerosis. Brain Res 2009;1296:216-224.
14. Choi MR, Kim HY, Park JY et al. Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 2010;472:94-98.
15. Vercelli A, Mereuta OM, Garbossa D et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2008;31:395-405.
16. Mazzini L, Ferrero I, Luparello V et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: A Phase I clinical trial. Exp Neurol 2010;223:229-237.
17. Kim H, Kim HY, Choi MR et al. Dosedependent efficacy of ALS-human mesenchymal stem cells transplantation into cisterna magna in SOD1-G93A ALS mice. Neurosci Lett 2010;468:190-194.
18. Kim HY PJ, Park HK, Choi MR, Yoon HS, Kim KS, Kim SH. Efficacy and safety of autologous bone marrow-derived mesenchymal stem cell treatment in patients with amyotrophic lateral sclerosis. J Korean Neurol Assoc 2009;27:163-169.
19. Habisch HJ, Janowski M, Binder D et al. Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: Limited intraparenchymal migration and survival narrows therapeutic effects. J Neural Transm 2007;114:1395-1406.
20. Corti S, Locatelli F, Papadimitriou D et al. Neural stem cells LewisX1 CXCR41 modify disease progression in an amyotrophic lateral sclerosis model. Brain 2007;130: 1289-1305.
21. von Bahr L, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012;30:1575-1578.
22. Lunn JS, Hefferan MP, Marsala M et al. Stem cells: Comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors 2009;27:133-140.
23. Bang OY, Lee JS, Lee PH et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005;57:874-882.
24. Lee JS, Hong JM, Moon GJ et al. A longterm follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells 2010;28:1099-1106.
25. Cho GW, Noh MY, Kim HY et al. Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev 2010;19:1035-1042.
26. Tovar-y-Romo LB, Tapia R. Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo. ASN Neuro 2012;4.
27. van Es MA, Schelhaas HJ, van Vught PW et al. Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 2011;70:964-973.
28. Phatnani HP, Guarnieri P, Friedman BA et al. Intricate interplay between astrocytes and motor neurons in ALS. Proc Natl Acad Sci U S A 2013;110:E756-765.
29. Audet JN, Gowing G, Paradis R et al. Ablation of proliferating cells in the CNS exacerbates motor neuron disease caused by mutant superoxide dismutase. PLoS One 2012;7:e34932.
30. Mazzini L, Fagioli F, Boccaletti R et al. Stem cell therapy in amyotrophic lateral sclerosis: A methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord 2003;4:158-161.
31. Mazzini L, Mareschi K, Ferrero I et al. Autologous mesenchymal stem cells: Clinical applications in amyotrophic lateral sclerosis. Neurol Res 2006;28:523-526.
32. Mazzini L, Mareschi K, Ferrero I et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008;265:78-83.
33. Karussis D, Karageorgiou C, Vaknin- Dembinsky A et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010;67:1187-1194.
34. Kassis I, Grigoriadis N, Gowda-Kurkalli B et al. Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch Neurol 2008;65:753-761.
35. Karussis D, Kassis I, Kurkalli BG et al. Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): A proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 2008; 265:131-135.
36. Einstein O, Grigoriadis N, Mizrachi-Kol R et al. Transplanted neural precursor cells reduce brain inflammation to attenuate chronic experimental autoimmune encephalomyelitis. Exp Neurol 2006;198:275-284.
37. Cho GW, Koh SH, Kim MH et al. The neuroprotective effect of erythropoietintransduced human mesenchymal stromal cells in an animal model of ischemic stroke. Brain Res 2010;1353:1-13.
38. Ringe J, Strassburg S, Neumann K et al. Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J Cell Biochem 2007;101:135-146.
39. Leigh PN, Swash M, Iwasaki Y et al. Amyotrophic lateral sclerosis: A consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;5:84-98.
40. Traynor BJ, Zhang H, Shefner JM et al. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004;63:1933-1935.
41. Kaufmann P, Levy G, Montes J et al. Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord 2007;8:42-46.
42. Kollewe K, Mauss U, Krampfl K et al. ALSFRS-R score and its ratio: A useful predictor for ALS-progression. J Neurol Sci 2008; 275:69-73.